Patents by Inventor Fenlai Tan

Fenlai Tan has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Glucagon like peptide analogs, composition, and method of use
    Patent number: 9487570
    Abstract: The present invention relates to novel analogs of glucagon like peptide and compositions that are useful for up-regulating insulin expression in mammals and for treating diabetes. In particular, these peptide derivatives have a peptide mimic linker and provides long duration of action for the treatment of diabetes and other insulinotropic peptide related diseases, gastrointestinal function and activities associated with glucagon levels.
    Type: Grant
    Filed: May 17, 2010
    Date of Patent: November 8, 2016
    Assignee: BETTA PHARMACEUTICALS CO., LTD
    Inventors: Shaojing Hu, Fenlai Tan, Yanping Wang, Cunbo Ma, Yunyan Hu, Hong Cao, Xiangdong Zhao, Wei Long, Yinxiang Wang, Lieming Ding
  • Compound for increasing kinase active and application thereof
    Patent number: 9409900
    Abstract: The compound of Formula (I), pharmaceutically acceptable salts thereof, solvates thereof, chelates thereof, non-covalent complexes thereof or produgs of compounds mentioned above or the mixture of any form above mentioned are provided. The use of the compounds in manufacturing a medicament for the treatment and/or prevention of diabetes, obesity and related disorders.
    Type: Grant
    Filed: November 9, 2011
    Date of Patent: August 9, 2016
    Assignees: FUJIAN HAIXI PHARMACEUTICALS, INC., BETTA PHARMACUETICALS CO., LTD.
    Inventors: Xinshan Kang, Wei Long, Cunbo Ma, Yanping Wang, Xiaoyan Shen, Yunyan Hu, Fenlai Tan, Yinxiang Wang
  • Icotinib hydrochloride, synthesis, crystalline forms, pharmaceutical compositions, and uses thereof
    Patent number: 9359370
    Abstract: The invention relates to 4-[(3-ethynylphenyl)amino]-6,7-benzo-12-crown-quinazoline hydrochloride, its new crystalline forms, its therapeutic usage for treatment of diseases mediated by EGFR kinase and its combinatory therapeutic usage together with other therapeutic agents. The invention also provides synthetic methods for preparation of 4-[(3-ethynylphenyl)amino]-6,7-benzo-12-crown-quinazoline hydrochloride, its new crystalline forms, and the relevant synthetic intermediates for synthesis of 4-[(3-ethynylphenyl)amino]-6,7-benzo-12-crown-quinazoline hydrochloride.
    Type: Grant
    Filed: July 31, 2014
    Date of Patent: June 7, 2016
    Assignee: Beta Pharma, Inc.
    Inventors: Yinxiang Wang, Guojian Xie, Lieming Ding, Fenlai Tan, Yunyan Hu, Wei He, Bin Han, Wei Long, Yong Liu, Haima Ai, Charles Davis, Don Zhang
  • Substituted fused heterocycles as c-Met tyrosine kinase inhibitors
    Patent number: 9242991
    Abstract: This invention relates to certain novel fused quinazoline derivatives (Formula I) as c-Met inhibitors which is shown as formula I, their synthesis and their use for treating a c-Met mediated disorder.
    Type: Grant
    Filed: July 14, 2011
    Date of Patent: January 26, 2016
    Assignee: BETTA PHARMACEUTICALS CO., LTD
    Inventors: Shaojing Hu, Fei Wang, Wei Long, Xiaoyan Shen, Fenlai Tan, Yinxiang Wang
  • Stable polymorphic forms of compound as hypoxia mimetics, and uses thereof
    Patent number: 9238637
    Abstract: The polymorphic forms of the compound of Formula I, the preparation thereof including the preparation of the intermediates, the pharmaceutical compositions thereof and the uses of a polymorph above in the manufacture of medicaments for treating a disease, a disorder or a condition are disclosed.
    Type: Grant
    Filed: July 30, 2012
    Date of Patent: January 19, 2016
    Assignee: BEIJING BETTA PHARMACEUTICALS CO., LTD
    Inventors: Xinshan Kang, Wei Long, Fei Wang, Cunbo Ma, Liufeng Zhou, Yunyan Hu, Yanping Wang, Hong Cao, Yinxiang Wang, Fenlai Tan
  • Glucagon-like peptide-1 analogues and uses thereof
    Patent number: 8951959
    Abstract: Provided is a glucagon-like peptide-1 (GLP-1) analog shown as the following formula, wherein X is selected from glycine and glycinamide. The GLP-1 analog has a non-proteogenic amino acid residue in position 8 relative to the sequence GLP-1, and is acylated with a moiety comprising two acidic groups to the lysine residue in position 26. The GLP-1 analog is resistant to dipeptidyl peptidase IV so as to have an extended half-life in vivo. Also provided is a use of the GLP-1 analog in conquering blood sugar.
    Type: Grant
    Filed: April 29, 2011
    Date of Patent: February 10, 2015
    Assignee: Betta Pharmaceuticals Co., Ltd.
    Inventors: Yinxiang Wang, Fenlai Tan, Shaojing Hu, Xiangdong Zhao, Cunbo Ma, Yanping Wang, Xiaoyan Shen, Lieming Ding, Yunyan Hu, Hong Cao, Wei Long
  • Stable Polymorphic Forms of Compound as Hypoxia Mimetics, and Uses Thereof
    Publication number: 20140343137
    Abstract: The polymorphic forms of the compound of Formula I, the preparation thereof including the preparation of the intermediates, the pharmaceutical compositions thereof and the uses of a polymorph above in the manufacture of medicaments for treating a disease, a disorder or a condition are disclosed.
    Type: Application
    Filed: July 30, 2012
    Publication date: November 20, 2014
    Applicants: BEIJING BETTA PHARMACEUTICALS CO., LTD.
    Inventors: Xinshan Kang, Wei Long, Fei Wang, Cunbo Ma, Liufeng Zhou, Yunyan Hu, Yanping Wang, Hong Cao, Yinxiang Wang, Fenlai Tan
  • ICOTINIB HYDROCHLORIDE, SYNTHESIS, CRYSTALLINE FORMS, PHARMACEUTICAL COMPOSITIONS, AND USES THEREOF
    Publication number: 20140343082
    Abstract: The invention relates to 4-[(3-ethynylphenyl)amino]-6,7-benzo-12-crown-quinazoline hydrochloride, its new crystalline forms, its therapeutic usage for treatment of diseases mediated by EGFR kinase and its combinatory therapeutic usage together with other therapeutic agents. The invention also provides synthetic methods for preparation of 4-[(3-ethynylphenyl)amino]-6,7-benzo-12-crown-quinazoline hydrochloride, its new crystalline forms, and the relevant synthetic intermediates for synthesis of 4-[(3-ethynylphenyl)amino]-6,7-benzo-12-crown-quinazoline hydrochloride.
    Type: Application
    Filed: July 31, 2014
    Publication date: November 20, 2014
    Inventors: Yinxiang Wang, Guojian Xie, Lieming Ding, Fenlai Tan, Yunyan Hu, Wei He, Bin Han, Wei Long, Yong Liu, Haima Ai, Charles Davis, Don Zhang
  • Icotinib hydrochloride, synthesis, crystalline forms, pharmaceutical compositions, and uses thereof
    Patent number: 8822482
    Abstract: The invention relates to 4-[(3-ethynylphenyl)amino]-6,7-benzo-12-crown-quinazoline hydrochloride, its new crystalline forms, its therapeutic usage for treatment of diseases mediated by EGFR kinase and its combinatory therapeutic usage together with other therapeutic agents. The invention also provides synthetic methods for preparation of 4-[(3-ethynylphenyl)amino]-6,7-benzo-12-crown-quinazoline hydrochloride, its new crystalline forms, and the relevant synthetic intermediates for synthesis of 4-[(3-ethynylphenyl)amino]-6,7-benzo-12-crown-quinazoline hydrochloride.
    Type: Grant
    Filed: July 7, 2009
    Date of Patent: September 2, 2014
    Assignee: Beta Pharma, Inc.
    Inventors: Yinxiang Wang, Guojian Xie, Lieming Ding, Fenlai Tan, Yunyan Hu, Wei He, Bin Han, Wei Long, Yong Liu, Haima Ai, Charles Davis, Don Zhang
  • Compounds as hypoxia mimetics, and compositions and uses thereof
    Patent number: 8742138
    Abstract: This invention relates to new compounds that can serve as hypoxia mimetics. This invention also relates to methods of increasing HIF levels or activity in a subject or treating a condition associated with HIF levels or activity in a subject by administering to the subject at least one of these compounds.
    Type: Grant
    Filed: July 14, 2010
    Date of Patent: June 3, 2014
    Assignees: Betta Pharmaceuticals Co., Ltd.
    Inventors: Xinshan Kang, Wei Long, Cunbo Ma, Yanping Wang, Hong Cao, Yinxiang Wang, Fenlai Tan, Yunyan Hu
  • COMPOUND FOR INCREASING KINASE ACTIVE AND APPLICATION THEREOF
    Publication number: 20130225587
    Abstract: The compound of Formula (I), pharmaceutically acceptable salts thereof, solvates thereof, chelates thereof, non-covalent complexes thereof or produgs of compounds mentioned above or the mixture of any form above mentioned are provided. The use of the compounds in manufacturing a medicament for the treatment and/or prevention of diabetes, obesity and related disorders.
    Type: Application
    Filed: November 9, 2011
    Publication date: August 29, 2013
    Applicants: Zhejiang Beta Pharma Incorporation, Fujian Haixi Pharmaceuticals, Inc.
    Inventors: Xinshan Kang, Wei Long, Cunbo Ma, Yanping Wang, Xiaoyan Shen, Yunyan Hu, Fenlai Tan, Yinxiang Wang
  • Novel Glucagon Like Peptide Analogs, Composition, and Method of Use
    Publication number: 20130203672
    Abstract: The present invention relates to novel analogs of glucagon like peptide and compositions that are useful for up-regulating insulin expression in mammals and for treating diabetes. In particular, these peptide derivatives have a peptide mimic linker and provides long duration of action for the treatment of diabetes and other insulinotropic peptide related diseases, gastrointestinal function and activities associated with glucagon levels.
    Type: Application
    Filed: May 17, 2010
    Publication date: August 8, 2013
    Inventors: Shaojing Hu, Fenlai Tan, Yanping Wang, Cunbo Ma, Yunyan Hu, Hong Cao, Xiangdong Zhao, Wei Long, Yinxiang Wang, Lieming Ding
  • Novel Fused Heterocyclic Derivatives Useful as c-Met Tyrosine Kinase Inhibitors
    Publication number: 20130123286
    Abstract: Certain novel fused quinazoline derivatives of formula (I) as c-Met inhibitors, their synthesis and their uses for treating a c-Met mediated disorder. Methods for treating a c-Met-mediated disorder are also disclosed in the invention.
    Type: Application
    Filed: July 14, 2011
    Publication date: May 16, 2013
    Inventors: Shaojing Hu, Fei Wang, Wei Long, Xiaoyan Shen, Fenlai Tan, Yinxiang Wang
  • GLUCAGON-LIKE PEPTIDE-1 ANALOGUES AND USES THEREOF
    Publication number: 20130053304
    Abstract: Provided is a glucagon-like peptide-1 (GLP-1) analogue shown as the following formula, wherein X is selected from glycine and glycinamide. The GLP-1 analogue has a non-proteogenic amino acid residue in position 8 relative to the sequence GLP-1, and is acylated with a moiety comprising two acidic groups to the lysine residue in position 26. The GLP-1 analogue is resistant to dipeptidyl peptidase IV so as to have an extended half-life in vivo. Also provided is a use of the GLP-1 analogue in conquering blood sugar.
    Type: Application
    Filed: April 29, 2011
    Publication date: February 28, 2013
    Inventors: Yinxiang Wang, Fenlai Tan, Shaojing Hu, Xiangdong Zhao, Cunbo Ma, Yanping Wang, Xiaoyan Shen, Lieming Ding, Yunyan Hu, Hong Cao, Wei Long
  • COMPOUNDS AS HYPOXIA MIMETICS, AND COMPOSIITONS AND USES THEREOF
    Publication number: 20120172399
    Abstract: This invention relates to new compounds that can serve as hypoxia mimetics. This invention also relates to methods of increasing HIF levels or activity in a subject or treating a condition associated with HIF levels or activity in a subject by administering to the subject at least one of these compounds.
    Type: Application
    Filed: July 14, 2010
    Publication date: July 5, 2012
    Inventors: Xinshan Kang, Wei Long, Cunbo Ma, Yanping Wang, Hong Cao, Yinxiang Wang, Fenlai Tan, Yunyan Hu
  • Icotinib Hydrochloride, Synthesis, Crystalline Forms, Pharmaceutical Compositions, and Uses Thereof
    Publication number: 20110182882
    Abstract: The invention relates to 4-[(3-ethynylphenyl)amino]-6,7-benzo-12-crown-quinazoline hydrochloride, its new crystalline forms, its therapeutic usage for treatment of diseases mediated by EGFR kinase and its combinatory therapeutic usage together with other therapeutic agents. The invention also provides synthetic methods for preparation of 4-[(3-ethynylphenyl)amino]-6,7-benzo-12-crown-quinazoline hydrochloride, its new crystalline forms, and the relevant synthetic intermediates for synthesis of 4-[(3-ethynylphenyl)amino]-6,7-benzo-12-crown-quinazoline hydrochloride.
    Type: Application
    Filed: July 7, 2009
    Publication date: July 28, 2011
    Applicant: Beta Pharma, Inc.
    Inventors: Yinxiang Wang, Guojian Xie, Lieming Ding, Fenlai Tan, Yunyan Hu, Wei He, Bin Han, Wei Long, Yong Liu, Haima Ai, Charles Davis, Don Zhang
  • NOVEL PLATINUM COMPOUNDS FOR TREATING CANCER
    Publication number: 20100152154
    Abstract: A series of platinum compounds and methods of treating cancer by said platinum compounds are disclosed.
    Type: Application
    Filed: December 12, 2009
    Publication date: June 17, 2010
    Inventors: Jiajiu Shaw, Fenlai Tan